Patient response to induction obinutuzumab by dose cohort
| Cohort . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | All . |
|---|---|---|---|---|---|---|---|
| Dose, mg | 100/200 | 200/400 | 400/800 | 800/1200 | 1200/2000 | 1000/1000 | |
| No. of patients | 3 | 3 | 3 | 3 | 3 | 7 | 22 |
| CR | 0 | ||||||
| PR (%) | 1 | 2 | 2 | 5 (23) | |||
| SD (%) | 1 | 1 | 2 | 3 | 5 | 12 (54) | |
| PD (%) | 1 | 1 | 1 | 1 | 4 (18) | ||
| Nonevaluable (%) | 1 | 1 (4) |
| Cohort . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | All . |
|---|---|---|---|---|---|---|---|
| Dose, mg | 100/200 | 200/400 | 400/800 | 800/1200 | 1200/2000 | 1000/1000 | |
| No. of patients | 3 | 3 | 3 | 3 | 3 | 7 | 22 |
| CR | 0 | ||||||
| PR (%) | 1 | 2 | 2 | 5 (23) | |||
| SD (%) | 1 | 1 | 2 | 3 | 5 | 12 (54) | |
| PD (%) | 1 | 1 | 1 | 1 | 4 (18) | ||
| Nonevaluable (%) | 1 | 1 (4) |
Twenty-one patients were evaluable for response, but only 20 were radiographically measurable. One patient with DLBCL died of PD before restaging radiologic assessment but was assessed as PD. One patient with CLL discontinued therapy during infusion 1 due to a grade 4 IRR and was inevaluable for response.